Ghrelin and MK-0677 restore GH amplitude, liver phenotype, and dopamine signaling in aging
Background
Aging is accompanied by progressive decline in growth hormone (GH) secretion, thymic function, liver metabolic homeostasis, and dopamine neurotransmission, collectively degrading body composition, immunity, and cognitive capacity. Current standard-of-care offers no unified intervention addressing these converging deficits. The growth hormone secretagogue receptor (GHS-R1a) is an endogenous receptor for the peptide ghrelin that regulates GH pulsatility, metabolism, and neuronal signaling. Age-associated reductions in endogenous ghrelin signaling may underlie several hallmarks of physiological decline, making GHS-R1a agonism a mechanistically plausible multi-system anti-aging target. The convergence of GHS-R1a with dopamine receptor subtype-1 (D1R) in key brain regions adds a neuromodulatory dimension beyond classical GH secretagogue effects.
Study Design
Studies spanned elderly human subjects, old mice, and cell culture models. MK-0677, an orally active GHS-R1a small-molecule agonist, was administered to elderly human subjects to assess restoration of GH pulse amplitude. In old mice, a similar GHS-R1a agonist was evaluated for thymic function and tumor cell growth/metastasis. Separately, old mice received the endogenous agonist ghrelin and liver nuclei were analyzed for cyclin D3:cdk4/cdk6 activity, PP2A activity, and C/EBPalpha phosphorylation state. Neuronal co-expression of GHS-R1a and D1R was mapped across hippocampus, cortex, substantia nigra, and ventral tegmental areas; heterodimer formation and G-protein signaling were assessed in cell culture with combined ghrelin and dopamine treatment.
Results
MK-0677 administration to elderly subjects restored GH pulse amplitude to levels characteristic of young adults, accompanied by increased lean mass, increased bone density, and modest improvements in strength. In old mice, a GHS-R1a agonist partially restored thymic function and reduced tumor cell growth and metastasis. Ghrelin treatment of old mice restored a young liver phenotype via inhibition of cyclin D3:cdk4/cdk6 activity and increased PP2A activity in liver nuclei, stabilizing the dephosphorylated form of transcription factor C/EBPalpha and preventing age-dependent formation of the C/EBPalpha-Rb-E2F4-Brm nuclear repressor complex — thereby de-repressing E2F target genes and normalizing Pepck-regulated gluconeogenesis.
Neurons co-expressing
GHS-R1aandD1Rwere identified in hippocampus, cortex, substantia nigra, and ventral tegmental areas; in the presence of both ghrelin and dopamine,GHS-R1aandD1Rformed heterodimers that amplified dopamine signaling via modified G-protein signal transduction.
Collectively, GHS-R1a agonism addressed liver metabolic aging, immune senescence, body composition, and neurological dopamine decline across multiple experimental systems.
Key Findings
- MK-0677 restored GH pulse amplitude in elderly subjects to levels seen in young adults
- Ghrelin treatment increased lean mass, bone density, and modestly improved strength
- GHS-R1a agonism partially restored thymic function and reduced tumor growth/metastasis in old mice
- Ghrelin restored young liver phenotype by blocking C/EBPalpha-Rb-E2F4-Brm complex and normalizing Pepck
- GHS-R1a and D1R form heterodimers that amplify dopamine signaling in multiple brain regions
Why It Matters
GHS-R1a agonists may represent a single-class intervention capable of addressing GH decline, metabolic liver aging, immune senescence, and dopaminergic deficits simultaneously — a breadth no current approved therapy matches. For clinicians and informed users, the human data on MK-0677 restoring GH pulsatility provides mechanistic justification for its use in body-composition and bone-density protocols in older adults, while the dopamine-amplification finding raises the possibility of cognitive and motor benefits. The C/EBPalpha-PP2A liver mechanism suggests that timing interventions to restore ghrelin tone may be especially relevant for metabolic health in aging populations. Translational distance remains moderate — human trials confirm GH and body-composition endpoints, but immune, oncologic, and dopaminergic benefits come from animal and cell data, requiring controlled human studies before protocol adoption.
TitrateLab articles covering MK-677
Written by TitrateLab, separately from the study summarized above.